BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1001 related articles for article (PubMed ID: 16098456)

  • 21. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current status and prospectives of aromatase inhibitors in the treatment of advanced breast cancer].
    Boccardo F
    Minerva Ginecol; 1998 Mar; 50(3):51-63. PubMed ID: 9595916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current status of adjuvant endocrine therapy for hormone responsive breast cancer].
    Ikeda T; Jinno H; Masamura S; Matsui A; Tajima G; Hohjoh T; Tokura H; Mitsui Y; Asaga S; Muto T; Fujiwara K; Kitajima M
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):902-8. PubMed ID: 11478138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation therapy plus tamoxifen versus tamoxifen alone after breast-conserving surgery in postmenopausal women with stage I breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Lee JH; Recht A
    J Clin Oncol; 2003 Jun; 21(12):2260-7. PubMed ID: 12805324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonal approaches to breast cancer treatment and prevention: an overview.
    Vogel CL
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine therapy of advanced disease: analysis and implications of the existing data.
    Pritchard KI
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):460S-7S. PubMed ID: 12538501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adjuvant treatment of breast cancer in 2004. A review of the 8th consensus conference of St. Gallen and new study results].
    Kahlert S; von Koch F; Ditsch N; Untch M
    Gynakol Geburtshilfliche Rundsch; 2004 Apr; 44(2):102-12. PubMed ID: 15073439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
    Friedrichs K; Jänicke F
    Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.
    Crivellari D; Price K; Gelber RD; Castiglione-Gertsch M; Rudenstam CM; Lindtner J; Fey MF; Senn HJ; Coates AS; Collins J; Goldhirsch A;
    J Clin Oncol; 2003 Dec; 21(24):4517-23. PubMed ID: 14673038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU
    Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
    Buzdar AU
    Clin Cancer Res; 2004 Jan; 10(1 Pt 2):355S-61S. PubMed ID: 14734491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Aromatase inhibitors: therapeutic outlook].
    Namer M
    Bull Cancer; 2000 Dec; 87 Spec No():41-5. PubMed ID: 11250607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
    Trunet PF; Vreeland F; Royce C; Chaudri HA; Cooper J; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
    Wong ZW; Ellis MJ
    Oncology (Williston Park); 2004 Apr; 18(4):411-20; discussion 421, 424, 429 passim. PubMed ID: 15134351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolving role of aromatase inhibitors in breast cancer.
    Mokbel K
    Int J Clin Oncol; 2002 Oct; 7(5):279-83. PubMed ID: 12402060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
    Buzdar A
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S42-8. PubMed ID: 12756078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.